1. Stocks
    2. /
  2. Mesoblast Limited (ASX: MSB)
    3. /

Mesoblast Limited (ASX: MSB) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Mesoblast Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • Mesoblast Limited (ASX: MSB)
    Latest News

    Five guys in suits wearing brightly coloured masks, they are corporate superheroes.
    Opinions

    5 ASX shares I'd buy with $10,000 this week

    | Samantha Menzies

    These are the ASX stocks I have my eye on this week.

    Read more »

    A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
    Opinions

    Forget CSL shares, I'd buy this booming biotech stock instead

    | Samantha Menzies

    This ASX biotech stock has caught my eye this year.

    Read more »

    A man wearing glasses and a white t-shirt pumps his fists in the air looking excited and happy about the rising OBX share price
    Broker Notes

    These ASX 200 shares could rise 30% to 40%

    | James Mickleboro

    Looking for big returns? Bell Potter thinks these shares could be the ones to buy.

    Read more »

    Four smiling young medics with arms crossed stand outside a hospital.
    Healthcare Shares

    How much further upside is there for Mesoblast shares after soaring 23% in a month?

    | Aaron Bell

    Could FDA approval send this healthcare stock towards further gains?

    Read more »

    A man looking at his laptop and thinking.
    Share Market News

    5 things to watch on the ASX 200 on Wednesday

    | James Mickleboro

    Let's see what awaits Aussie investors during today's session.

    Read more »

    Winning woman smiles and holds big cup while losing woman looks unhappy with small cup
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a dour Tuesday for ASX investors.

    Read more »

    woman in lab coat conducting testing representing biotech
    Healthcare Shares

    Is this soaring ASX 200 healthcare share just getting started?

    | Marc Van Dinther

    If its lead therapy gets US approval, the stock can continue to climb.

    Read more »

    A neon sign says 'Top Ten'.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a Garfield kind of Monday for investors.

    Read more »

    An old-fashioned panel of judges each holding a card with the number 10
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a happy end to the trading week this Friday.

    Read more »

    Male investor holds a microscope to his eye to represent scrutiny of Wesfarmers share price
    Healthcare Shares

    Mesoblast shares: Bull vs. bear

    | Bronwyn Allen

    Two experts have presented their case for buying and selling the ASX biotech stock.

    Read more »

    A panel of four judges hold up cards all showing the perfect score of ten out of ten
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a happy hump day for the markets.

    Read more »

    Three trophies in declining sizes with a red curtain backdrop
    Share Market News

    Leading analysts name 3 ASX 200 titans to buy today

    | Bernd Struben

    Top analysts forecast strong returns from these three ASX 200 titans. Let’s see why.

    Read more »

    Frequently Asked Questions

    No, Mesoblast does not pay shareholder dividends at this time.

    Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.

    Mesoblast Ltd listed on the ASX on 16 December 2004.

    MSB ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Mesoblast Limited

    Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.

    Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines. 

    Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).

    Profile

    since

    Note